Stable sodium channel blockers

a sodium channel blocker and stable technology, applied in the field of epithelial sodium channel blockers, can solve the problems of hyperkalemia and death, and achieve the effect of slow reversibility and slow absorbing

Inactive Publication Date: 2015-12-31
PARION SCI DURHAM NC
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]It is an object of the present invention to provide a compound that is an epithelial sodium channel blocker that is potent in vivo, slowly absorbed from mucosal surfaces, slowly reversible and excerted largely non-renall

Problems solved by technology

This compound must also cause its actions topically (eye, nose, lung) at dose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stable sodium channel blockers
  • Stable sodium channel blockers
  • Stable sodium channel blockers

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Compound 13

[0165]To a solution of benzyl 4-(4-hydroxyphenyl)butylcarbamate (11, 10.0 g, 33.4 mmol) in dry THF (100 mL) was added N-Boc ethanolamine (12, 13.4 g, 83.5 mmol), Ph3P (21.8 g, 83.5 mmol) and DIAD (16.8 g, 83.5 mmol) at 0° C., then the reaction mixture was warmed to room temperature and stirred over night. The reaction mixture was concentrated in vacuum and the residue was purified by column (silica gel, 95:5 CHCl3 / MeOH) to afford compound 3 (9.0 g, 64%) as a yellow solid: 1H NMR (400 MHz, CDCl3) δ 7.35-7.34 (m, 5H), 7.10 (d, J=8.0 Hz, 2H), 6.80 (d, J=8.0 Hz, 2H), 5.10 (s, J=4.0 Hz, 2H), 4.01-3.98 (m, 2H), 3.5 (q, 2H), 3.2 (q, 2H), 2.55 (t, J=8.0 Hz, 2H), 1.60-1.49 (m, 4H), 1.45 (s, 9H).

example 2

Preparation of Benzyl 4-(4-(2-aminoethoxyl)phenyl)butylcarbamate Hydrochloric Acid Salt (14)

[0166]Compound 13 (9.0 g, 20.3 mmol) was dissolved in 4 N HCl in dioxane (50 mL) at room temperature and the solution was stirred for 1 h. After concentrated, the residue was suspended in MTBE (250 mL) and stirred for 0.5 h. The solid is filtered out to afford hydrochloric acid salt 14 (7.6 g, 90%) as a white solid: 1H NMR (300 MHz, CD3OD) δ 7.33-7.32 (m, 5H), 7.10 (d, J=8.7 Hz, 2H), 6.88 (d, J=8.7 Hz, 2H), 5.05 (s, 2H), 4.18 (t, 2H), 3.39-3.31 (m, 2H), 3.11 (t, J=7.2 Hz, 2H), 2.56 (t, J=7.5 Hz, 2H), 1.59-1.49 (m, 4H).

example 3

Preparation of Compound 16

[0167]To a solution of compound 14 (5.6 g, 21.8 mmol) in dry THF (250 mL) was added DIPEA (12.0 mL, 65.4 mmol), DEPBT (8.4 g, 28.3 mmol) and compound 15 (11.1 g, 23.9 mmol). The reaction mixture was stirred at room temperature overnight and concentrated in vacuum. The residue was purified by column chromatography (silica gel, 95:5 CHCl3 / MeOH) to afford desired compound 16 (7.6 g, 71%) as a white solid: 1H NMR (400 MHz, CD3OD) δ 7.75 (d, J=7.4 Hz, 2H), 7.63 (d, J=7.4 Hz, 2H), 7.39-7.26 (m, 9H), 7.00 (d, J=8.0 Hz, 2H), 6.76 (d, J=8.0 Hz, 2H), 5.04 (s, 2H), 4.32 (d, J=6.4 Hz, 2H), 4.16 (t, J=6.8 Hz, 1H), 4.04 (t, J=8.0 Hz, 1H), 3.97 (t, J=5.2 Hz, 2H), 3.60-3.49 (m, 2H), 3.09 (t, J=6.8 Hz, 2H), 2.97 (t, J=6.4 Hz, 2H), 2.48-2.47 (m, 2H), 1.72-1.30 (m, 19H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sizeaaaaaaaaaa
Hydration numberaaaaaaaaaa
Login to view more

Abstract

A very stable, selective and renally safe sodium channel blocker represented by the formula:
The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The present invention relates to epithelial sodium channel blocker 3,5-diamino-6-chloro-N—(N-(4-(4-(2-((S)-6-guanidino-2-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexylamino)hexanamido)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (I). The present invention also includes a variety of methods of treatment using this inventive sodium channel blocker.[0003]2. Description of the Background[0004]The mucosal surfaces at the interface between the environment and the body have evolved a number of “innate defense”, i.e., protective mechanisms. A principal form of such innate defense is to cleanse these surfaces with liquid. Typically, the quantity of the liquid layer on a mucosal surface reflects the balance between epithelial liquid secretion, often reflecting anion (Cl− and / or HCO3−) secretion coupled with water (and a cation counter-ion), and epithelial liquid absorption, often reflecting Na+ absorption, coupled with wa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D241/26A61K45/06A61K31/4965
CPCC07D241/26Y02A50/406A61K45/06A61K31/4965Y02A50/30
Inventor JOHNSON, MICHAEL R.
Owner PARION SCI DURHAM NC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products